Migraine and contraceptives: Clinical considerations

Migraine affects three times more women than men, with hormonal changes being key factors in its triggering. Hormonal contraceptives can be useful, but also risky if not selected judiciously.

Roles of estrogen and progesterone

  • Hormonal fluctuations: Decreases in estrogen during the luteal phase or menstruation trigger migraine in up to 60% of patients.
  • Prostaglandins: They increase after the drop in estrogen, contributing to inflammation and pain.
Ciclo hormonal y desencadenamiento de migraña
Figure 1: Relationship between the menstrual cycle and the appearance of migraine. The episodes usually coincide with the drop in estrogen in the luteal phase.

Hormonal therapies: Efficacy and risks

  • Combined oral contraceptives: They can prevent migraine in patients with a menstrual pattern, but are contraindicated if there is a migraine with aura (increases the risk of stroke).
  • Progestin-only IUD: May worsen migraine in some patients; IUD with estrogen or without hormones is preferred.
  • Estrogen stimulation (patches/subcutaneous): Useful in postmenopausal women or women with hypogonadism, but at risk of thrombosis.
Efectos de diferentes anticonceptivos en la frecuencia de migraña
Figure 2: Effects of different contraceptive methods on migraine frequency. Combined drugs (with estrogen) reduce episodes in some patients, but progestin-only drugs can increase them.

Associated conditions and key considerations

  • PCOS and endometriosis: They are associated with a greater frequency of migraines due to inflammation and hormonal imbalances.
  • Transgender women on hormone therapy: They may experience changes in migraine frequency; Individualized evaluation is required.
  • First step: Evaluate the migraine pattern (with/without aura), history of cardiovascular events and risk factors.

Conclusion: Hormonal contraceptives are not recommended in migraine with aura. Therapy must be individualized, with close monitoring.

Source details

• Van Lohuizen et al. (2023): Critical review of hormonal therapies in migraine. Highlights the need for personalized strategies.

• EFNS (2009): Pharmacological treatment recommendations. It does not include contraceptives as a first line, but confirms contraindications in migraine with aura.